Company News: Page (1) of 1 - 07/15/14 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Johnson & Johnson Reports 2014 Second-Quarter Results:

Sales of $19.5 Billion increased 9.1% Versus 2013 Second Quarter;Second-Quarter EPS was $1.51Excluding Special Items, 2014 Second-Quarter EPS of $1.66 increased 12.2%* (July 15, 2014)

NEW BRUNSWICK, N.J., July 15, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%. Domestic sales increased 14.9%. International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%.

Net earnings and diluted earnings per share for the second quarter of 2014 were $4.3 billion and $1.51, respectively. The second-quarter results included a charge for after-tax special items of approximately $0.4 billion, primarily related to an increase in the litigation accrual as well as integration and transaction costs related to the acquisition of Synthes, Inc. Second quarter 2013 net earnings included a charge for after-tax special items of approximately $0.5 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $4.8 billion and diluted earnings per share were $1.66, representing increases of 11.3% and 12.2%, respectively, as compared to the same period in 2013.*

"Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities," said Alex Gorsky, Chairman and Chief Executive Officer. "Significant advancementsare being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market."


The Company increased its earnings guidance for full-year 2014 to $5.85 - $5.92 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 2.4% versus the prior year consisting of an operational increase of 3.6% and a negative impact from currency of 1.2%.

Domestic sales decreased 0.5% primarily reflecting the divestiture of the sanitary protection business. International sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.

Positive contributors to operational results were sales of TYLENOL and MOTRIN analgesics; over-the-counter upper respiratory medicines as well as anti-smoking aids; NEUTROGENA and AVEENO skin care products; baby care products; and international sales of LISTERINE mouthwash and feminine protection products.

Worldwide Pharmaceutical sales of $8.5 billion for the second quarter represented an increase of 21.1% versus the prior year on a total and operational basis. Domestic sales increased 36.6%. International sales increased 6.8% which reflected an operational increase of 6.9% and a negative currency impact of 0.1%.

The strong sales results were primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for combination treatment of chronic hepatitis C in adult patients; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA (canagliflozin), for the treatment of adults with type 2 diabetes; and IMBRUVICA (ibrutinib), a kinase inhibitor for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in patients who have had at least one prior therapy.

Additional contributors to operational sales growth were STELARA (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; REMICADE (infliximab) and SIMPONI/SIMPONI ARIA (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; and PREZISTA (darunavir), a treatment for HIV.

Sales results were negatively impacted by loss of exclusivity for ACIPHEX (rabeprazole), a proton pump inhibitor for gastrointestinal disorders, and CONCERTA (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.

During the quarter, the U.S. Food and Drug Administration (FDA) and the European Commission (EC) granted approval of SYLVANT (siltuximab) for the treatment of patients with multicentric Castleman's disease who are human immunodeficiency virus negative and human herpesvirus-8 negative. In addition, the EC granted approval for VOKANAMET, a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet for the treatment of adults with type 2 diabetes; OLYSIO (simeprevir) for the treatment of adult patients with genotype 1 or 4 chronic hepatitis C; and for INVEGA (paliperidone ER) to extend its adult indication of schizophrenia to include adolescents aged 15 years and older.

In addition, a supplemental New Drug Application (sNDA) was submitted to the FDA seeking approval for simeprevir in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc. Additional sNDA's were also submitted to the FDA for once-monthly atypical long-acting antipsychotic INVEGA SUSTENNA (paliperidone palmitate) for approval to treat schizoaffective disorder as either monotherapy or adjunctive therapy.

A Marketing Authorization Application was submitted to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma.

Worldwide Medical Devices and Diagnostics sales of $7.2 billion for the second quarter represented an increase of 0.7% versus the prior year consisting of an operational increase of 0.9% and a negative currency impact of 0.2%. Domestic sales decreased 1.4%. International sales increased 2.3%, which reflected an operational increase of 2.6% and a negative currency impact of 0.3%.

Primary contributors to operational growth were hip and trauma products in the Orthopaedics business, Biosense Webster's electrophysiology products in the Cardiovascular Care business, and sales of energy products in the Specialty Surgery business.

Sales results in the U.S. Diabetes Care business were negatively impacted by price declines associated with the implementation of Medicare competitive bidding in mail order and retail effective July 1, 2013.

During the quarter, the SABER PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease received FDA and EC approval.

Subsequent to the quarter, on June 30, the Company completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,000 employees at more than 270 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; the impact of patent expirations; challenges to patents; significant adverse litigation or government action, including related to product liability claims; impact of business combinations and divestitures; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays, internally or within the supply chain; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date on which it is made. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data






















(Unaudited; Dollars in Millions)


SECOND QUARTER


SIX MONTHS







Percent Change






Percent Change



2014


2013


Total


Operations


Currency


2014


2013


Total


Operations


Currency

Sales to customers by





















segment of business










































Consumer





















U.S.


$ 1,320


1,326


(0.5)

%

(0.5)


-


$ 2,629


2,674


(1.7)

%

(1.7)


-

International


2,424


2,332


3.9


5.8


(1.9)


4,672


4,659


0.3


3.3


(3.0)



3,744


3,658


2.4


3.6


(1.2)


7,301


7,333


(0.4)


1.5


(1.9)






















Pharmaceutical





















U.S.


4,613


3,377


36.6


36.6


-


8,353


6,848


22.0


22.0


-

International


3,896


3,648


6.8


6.9


(0.1)


7,654


6,945


10.2


11.6


(1.4)



8,509


7,025


21.1


21.1


0.0


16,007


13,793


16.1


16.8


(0.7)






















Med Devices & Diagnostics





















U.S.


3,199


3,243


(1.4)


(1.4)


-


6,354


6,449


(1.5)


(1.5)


-

International


4,043


3,951


2.3


2.6


(0.3)


7,948


7,807


1.8


3.6


(1.8)



7,242


7,194


0.7


0.9


(0.2)


14,302


14,256


0.3


1.3


(1.0)






















U.S.


9,132


7,946


14.9


14.9


-


17,336


15,971


8.5


8.5


-

International


10,363


9,931


4.4


5.0


(0.6)


20,274


19,411


4.4


6.4


(2.0)

Worldwide


$ 19,495


17,877


9.1

%

9.4


(0.3)


$ 37,610


35,382


6.3

%

7.4


(1.1)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data





















(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2014


2013


Total


Operations


Currency


2014


2013


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$ 9,132


7,946


14.9

%

14.9


-


$ 17,336


15,971


8.5

%

8.5


-





















Europe

5,056


4,672


8.2


4.1


4.1


9,941


9,153


8.6


5.3


3.3

Western Hemisphere excluding U.S.

1,863


1,905


(2.2)


6.5


(8.7)


3,558


3,688


(3.5)


6.8


(10.3)

Asia-Pacific, Africa

3,444


3,354


2.7


5.3


(2.6)


6,775


6,570


3.1


7.7


(4.6)

International

10,363


9,931


4.4


5.0


(0.6)


20,274


19,411


4.4


6.4


(2.0)





















Worldwide

$ 19,495


17,877


9.1

%

9.4


(0.3)


$ 37,610


35,382


6.3

%

7.4


(1.1)

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings











(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER












2014


2013


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 19,495


100.0


$ 17,877


100.0


9.1

Cost of products sold

6,039


31.0


5,489


30.7


10.0

Selling, marketing and administrative expenses

5,481


28.1


5,376


30.1


2.0

Research and development expense

2,005


10.3


1,946


10.9


3.0

In-process research and development

4


0.0


-


-



Interest (income) expense, net

114


0.6


101


0.6



Other (income) expense, net

226


1.1


172


0.9



Earnings before provision for taxes on income

5,626


28.9


4,793


26.8


17.4

Provision for taxes on income

1,300


6.7


960


5.4


35.4

Net earnings

$ 4,326


22.2


$ 3,833


21.4


12.9











Net earnings per share (Diluted)

$ 1.51




$ 1.33




13.5











Average shares outstanding (Diluted)

2,874.2




2,893.0















Effective tax rate

23.1

%



20.0

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$ 6,050


31.0


$ 5,359


30.0


12.9

Net earnings

$ 4,775


24.5


$ 4,289


24.0


11.3

Net earnings per share (Diluted)

$ 1.66




$ 1.48




12.2

Effective tax rate

21.1

%



20.0

%














(1) See Reconciliation of Non-GAAP Financial Measures.








Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings











(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS












2014


2013


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 37,610


100.0


$ 35,382


100.0


6.3

Cost of products sold

11,494


30.6


11,043


31.2


4.1

Selling, marketing and administrative expenses

10,664


28.3


10,599


30.0


0.6

Research and development expense

3,836


10.2


3,730


10.5


2.8

In-process research and development

22


0.1


64


0.2



Interest (income) expense, net

232


0.6


205


0.6



Other (income) expense, net

312


0.8


687


1.9



Earnings before provision for taxes on income

11,050


29.4


9,054


25.6


22.0

Provision for taxes on income

1,997


5.3


1,724


4.9


15.8

Net earnings

$ 9,053


24.1


$ 7,330


20.7


23.5











Net earnings per share (Diluted)

$ 3.15




$ 2.55




23.5











Average shares outstanding (Diluted)

2,875.5




2,878.8















Effective tax rate

18.1

%



19.0

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$ 11,610


30.9


$ 10,429


29.5


11.3

Net earnings

$ 9,201


24.5


$ 8,396


23.7


9.6

Net earnings per share (Diluted)

$ 3.20




$ 2.92




9.6

Effective tax rate

20.7

%



19.5

%














(1) See Reconciliation of Non-GAAP Financial Measures.








Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures
















Second Quarter


% Incr. /



Six Months YTD


% Incr. /


(Dollars in Millions Except Per Share Data)

2014


2013


(Decr.)



2014


2013


(Decr.)
















Earnings before provision for taxes on income - as reported

$ 5,626


4,793


17.4

%


$ 11,050


9,054


22.0

%















Litigation expenses

276


375





276


904


















Synthes integration/transaction costs

144


122





262


380


















In-process research and development

4


-





22


64


















DePuy ASRHip program

-


69





-


82


















Other

-


-





-


(55)


















Earnings before provision for taxes on income - as adjusted

$ 6,050


5,359


12.9

%


$ 11,610


10,429


11.3

%















Net Earnings - as reported

$ 4,326


3,833


12.9

%


$ 9,053


7,330


23.5

%















Litigation expenses

342

(1)

308





342


699


















Synthes integration/transaction costs

104


87





188


270


















In-process research and development

3


-





16


42


















DePuy ASRHip program

-


61





-


91


















Tax benefit associated with Conor Medsystems

-


-





(398)


-


















Other

-


-





-


(36)


















Net Earnings - as adjusted

$ 4,775


4,289


11.3

%


$ 9,201


8,396


9.6

%















Diluted Net Earnings per share - as reported

$ 1.51


1.33


13.5

%


$ 3.15


2.55


23.5

%















Litigation expenses

0.12


0.10





0.12


0.24


















Synthes integration/transaction costs

0.03


0.03





0.06


0.09


















In-process research and development

-


-





0.01


0.02


















DePuy ASRHip program

-


0.02





-


0.03


















Tax benefit associated with Conor Medsystems

-


-





(0.14)


-


















Other

-


-





-


(0.01)


















Diluted Net Earnings per share - as adjusted

$ 1.66


1.48


12.2

%


$ 3.20


2.92


9.6

%















(1) Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction























The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxeson income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER



SIX MONTHS






% Change







% Change



2014


2013

Reported

Operational (1)

Currency




2014


2013

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2)

















BABY CARE

















US


$ 107


106

0.9%

0.9%

-




$ 209


209

0.0%

0.0%

-

Intl


500


480

4.2%

8.6%

-4.4%




943


941

0.2%

5.5%

-5.3%

WW


607


586

3.6%

7.2%

-3.6%




1,152


1,150

0.2%

4.6%

-4.4%

ORAL CARE

















US


142


149

-4.7%

-4.7%

-




302


307

-1.6%

-1.6%

-

Intl


271


257

5.4%

7.3%

-1.9%




522


502

4.0%

7.2%

-3.2%

WW


413


406

1.7%

2.9%

-1.2%




824


809

1.9%

3.9%

-2.0%

OTC

















US


316


290

9.0%

9.0%

-




682


644

5.9%

5.9%

-

Intl


687


641

7.2%

7.4%

-0.2%




1,332


1,330

0.2%

1.7%

-1.5%

WW


1,003


931

7.7%

7.8%

-0.1%




2,014


1,974

2.0%

3.0%

-1.0%

SKIN CARE

















US


506


463

9.3%

9.3%

-




963


916

5.1%

5.1%

-

Intl


462


445

3.8%

4.2%

-0.4%




919


894

2.8%

4.4%

-1.6%

WW


968


908

6.6%

6.8%

-0.2%




1,882


1,810

4.0%

4.8%

-0.8%

WOMEN'S HEALTH

















US


11


84

-86.9%

-86.9%

-




35


165

-78.8%

-78.8%

-

Intl


331


327

1.2%

5.4%

-4.2%




634


647

-2.0%

3.3%

-5.3%

WW


342


411

-16.8%

-13.5%

-3.3%




669


812

-17.6%

-13.4%

-4.2%

WOUND CARE/OTHER

















US


238


234

1.7%

1.7%

-




438


433

1.2%

1.2%

-

Intl


173


182

-4.9%

-4.4%

-0.5%




322


345

-6.7%

-5.4%

-1.3%

WW


411


416

-1.2%

-1.0%

-0.2%




760


778

-2.3%

-1.7%

-0.6%


















TOTAL CONSUMER

















US


1,320


1,326

-0.5%

-0.5%

-




2,629


2,674

-1.7%

-1.7%

-

Intl


2,424


2,332

3.9%

5.8%

-1.9%




4,672


4,659

0.3%

3.3%

-3.0%

WW


$ 3,744


3,658

2.4%

3.6%

-1.2%




$ 7,301


7,333

-0.4%

1.5%

-1.9%



































See footnotes at end of schedule
















REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER



SIX MONTHS






% Change







% Change



2014


2013

Reported

Operational (1)

Currency




2014


2013

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (3)

















IMMUNOLOGY

















US


$ 1,853


1,578

17.4%

17.4%

-




$ 3,400


3,217

5.7%

5.7%

-

Intl


778


663

17.3%

19.1%

-1.8%




1,574


1,228

28.2%

31.8%

-3.6%

WW


2,631


2,241

17.4%

17.9%

-0.5%




4,974


4,445

11.9%

12.9%

-1.0%

REMICADE

















US


1,021


926

10.3%

10.3%

-




2,018


1,896

6.4%

6.4%

-

US Exports (4)


357


332

7.5%

7.5%

-




524


681

-23.1%

-23.1%

-

Intl


426


414

2.9%

6.3%

-3.4%




872


695

25.5%

31.0%

-5.5%

WW


1,804


1,672

7.9%

8.7%

-0.8%




3,414


3,272

4.3%

5.5%

-1.2%

SIMPONI/SIMPONI ARIA

















US


132


87

51.7%

51.7%

-




236


181

30.4%

30.4%

-

Intl


150


88

70.5%

71.3%

-0.8%




305


231

32.0%

34.7%

-2.7%

WW


282


175

61.1%

61.5%

-0.4%




541


412

31.3%

32.8%

-1.5%

STELARA

















US


343


233

47.2%

47.2%

-




622


459

35.5%

35.5%

-

Intl


185


138

34.1%

31.4%

2.7%




362


258

40.3%

39.2%

1.1%

WW


528


371

42.3%

41.3%

1.0%




984


717

37.2%

36.8%

0.4%

OTHER IMMUNOLOGY

















US


-


-

-

-

-




-


-

-

-

-

Intl


17


23

-26.1%

-22.7%

-3.4%




35


44

-20.5%

-14.6%

-5.9%

WW


17


23

-26.1%

-22.7%

-3.4%




35


44

-20.5%

-14.6%

-5.9%

INFECTIOUS DISEASES

















US


1,020


259

*

*

-




1,581


497

*

*

-

Intl


742


711

4.4%

3.5%

0.9%




1,381


1,288

7.2%

6.6%

0.6%

WW


1,762


970

81.6%

80.9%

0.7%




2,962


1,785

65.9%

65.5%

0.4%

EDURANT

















US


6


3

100.0%

100.0%

-




11


6

83.3%

83.3%

-

Intl


86


53

62.3%

57.7%

4.6%




162


93

74.2%

70.3%

3.9%

WW


92


56

64.3%

60.0%

4.3%




173


99

74.7%

71.0%

3.7%

INCIVO

















US


-


-

-

-

-




-


-

-

-

-

Intl


97


172

-43.6%

-42.5%

-1.1%




183


334

-45.2%

-44.8%

-0.4%

WW


97


172

-43.6%

-42.5%

-1.1%




183


334

-45.2%

-44.8%

-0.4%

OLYSIO/SOVRIAD

















US


725


-

*

*

-




1,016


-

*

*

-

Intl


106


-

*

*

0.0%




169


-

*

*

0.0%

WW


831


-

*

*

0.0%




1,185


-

*

*

0.0%

PREZISTA

















US


239


196

21.9%

21.9%

-




453


363

24.8%

24.8%

-

Intl


253


239

5.9%

4.7%

1.2%




484


439

10.3%

9.6%

0.7%

WW


492


435

13.1%

12.4%

0.7%




937


802

16.8%

16.4%

0.4%

OTHER INFECTIOUS DISEASES

















US


50


60

-16.7%

-16.7%

-




101


128

-21.1%

-21.1%

-

Intl


200


247

-19.0%

-19.6%

0.6%




383


422

-9.2%

-9.0%

-0.2%

WW


250


307

-18.6%

-19.0%

0.4%




484


550

-12.0%

-11.9%

-0.1%




















REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER



SIX MONTHS






% Change







% Change



2014


2013

Reported

Operational (1)

Currency




2014


2013

Reported

Operational (1)

Currency


















NEUROSCIENCE

















US


600


626

-4.2%

-4.2%

-




1,201


1,372

-12.5%

-12.5%

-

Intl


1,027


1,054

-2.6%

-2.4%

-0.2%




2,064


2,052

0.6%

2.5%

-1.9%

WW


1,627


1,680

-3.2%

-3.1%

-0.1%




3,265


3,424

-4.6%

-3.5%

-1.1%

CONCERTA/METHYLPHENIDATE

















US


28


85

-67.1%

-67.1%

-




63


224

-71.9%

-71.9%

-

Intl


117


130

-10.0%

-8.3%

-1.7%




232


247

-6.1%

-3.0%

-3.1%

WW


145


215

-32.6%

-31.6%

-1.0%




295


471

-37.4%

-35.8%

-1.6%

INVEGA

















US


89


76

17.1%

17.1%

-




175


147

19.0%

19.0%

-

Intl


69


74

-6.8%

-7.5%

0.7%




148


135

9.6%

11.3%

-1.7%

WW


158


150

5.3%

5.0%

0.3%




323


282

14.5%

15.3%

-0.8%

INVEGA SUSTENNA/ XEPLION

















US


202


158

27.8%

27.8%

-




384


322

19.3%

19.3%

-

Intl


192


132

45.5%

42.3%

3.2%




383


252

52.0%

51.0%

1.0%

WW


394


290

35.9%

34.4%

1.5%




767


574

33.6%

33.2%

0.4%

RISPERDAL CONSTA

















US


110


107

2.8%

2.8%

-




216


213

1.4%

1.4%

-

Intl


192


229

-16.2%

-17.7%

1.5%




396


458

-13.5%

-13.4%

-0.1%

WW


302


336

-10.1%

-11.1%

1.0%




612


671

-8.8%

-8.7%

-0.1%

OTHER NEUROSCIENCE

















US


171


200

-14.5%

-14.5%

-




363


466

-22.1%

-22.1%

-

Intl


457


489

-6.5%

-4.9%

-1.6%




905


960

-5.7%

-2.4%

-3.3%

WW


628


689

-8.9%

-7.8%

-1.1%




1,268


1,426

-11.1%

-8.9%

-2.2%

ONCOLOGY

















US


278


206

35.0%

35.0%

-




518


405

27.9%

27.9%

-

Intl


833


679

22.7%

21.6%

1.1%




1,615


1,274

26.8%

27.1%

-0.3%

WW


1,111


885

25.5%

24.6%

0.9%




2,133


1,679

27.0%

27.2%

-0.2%

VELCADE

















US


-


-

-

-

-




-


-

-

-

-

Intl


403


379

6.3%

6.2%

0.1%




811


732

10.8%

12.2%

-1.4%

WW


403


379

6.3%

6.2%

0.1%




811


732

10.8%

12.2%

-1.4%

ZYTIGA

















US


235


174

35.1%

35.1%

-




464


335

38.5%

38.5%

-

Intl


327


221

48.0%

45.1%

2.9%




610


404

51.0%

49.4%

1.6%

WW


562


395

42.3%

40.7%

1.6%




1,074


739

45.3%

44.4%

0.9%

OTHER ONCOLOGY

















US


43


32

34.4%

34.4%

-




54


70

-22.9%

-22.9%

-

Intl


103


79

30.4%

29.2%

1.2%




194


138

40.6%

40.7%

-0.1%

WW


146


111

31.5%

30.6%

0.9%




248


208

19.2%

19.2%

0.0%




















REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER



SIX MONTHS






% Change







% Change



2014


2013

Reported

Operational (1)

Currency




2014


2013

Reported

Operational (1)

Currency

TOTAL OTHER

















US


862


708

21.8%

21.8%

-




1,653


1,357

21.8%

21.8%

-

Intl


516


541

-4.6%

-4.7%

0.1%




1,020


1,103

-7.5%

-6.7%

-0.8%

WW


1,378


1,249

10.3%

10.3%

0.0%




2,673


2,460

8.7%

9.0%

-0.3%

PROCRIT/EPREX

















US


178


190

-6.3%

-6.3%

-




354


423

-16.3%

-16.3%

-

Intl


141


145

-2.8%

-3.4%

0.6%




275


290

-5.2%

-5.0%

-0.2%

WW


319


335

-4.8%

-5.1%

0.3%




629


713

-11.8%

-11.7%

-0.1%

XARELTO

















US


361


189

91.0%

91.0%

-




680


347

96.0%

96.0%

-

Intl


-


-

-

-

-




-


-

-

-

-

WW


361


189

91.0%

91.0%

-




680


347

96.0%

96.0%

-

OTHER

















US


323


329

-1.8%

-1.8%

-




619


587

5.5%

5.5%

-

Intl


375


396

-5.3%

-5.1%

-0.2%




745


813

-8.4%

-7.4%

-1.0%

WW


698


725

-3.7%

-3.6%

-0.1%




1,364


1,400

-2.6%

-2.0%

-0.6%


















TOTAL PHARMACEUTICAL

















US


4,613


3,377

36.6%

36.6%

-




8,353


6,848

22.0%

22.0%

-

Intl


3,896


3,648

6.8%

6.9%

-0.1%




7,654


6,945

10.2%

11.6%

-1.4%

WW


$ 8,509


7,025

21.1%

21.1%

0.0%




$ 16,007


13,793

16.1%

16.8%

-0.7%




















































See footnotes at end of schedule
















REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER



SIX MONTHS






% Change







% Change



2014


2013

Reported

Operational (1)

Currency




2014


2013

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2) (3)

















CARDIOVASCULAR CARE

















US


$ 214


204

4.9%

4.9%

-




$ 419


402

4.2%

4.2%

-

Intl


353


325

8.6%

8.7%

-0.1%




689


640

7.7%

9.1%

-1.4%

WW


567


529

7.2%

7.3%

-0.1%




1,108


1,042

6.3%

7.2%

-0.9%

DIABETES CARE

















US


222


259

-14.3%

-14.3%

-




414


542

-23.6%

-23.6%

-

Intl


336


330

1.8%

1.8%

0.0%




656


647

1.4%

2.4%

-1.0%

WW


558


589

-5.3%

-5.3%

0.0%




1,070


1,189

-10.0%

-9.5%

-0.5%

DIAGNOSTICS

















US


232


241

-3.7%

-3.7%

-




456


489

-6.7%

-6.7%

-

Intl


229


242

-5.4%

-4.3%

-1.1%




448


471

-4.9%

-2.6%

-2.3%

WW


461


483

-4.6%

-4.1%

-0.5%




904


960

-5.8%

-4.7%

-1.1%

ORTHOPAEDICS

















US


1,294


1,274

1.6%

1.6%

-




2,586


2,535

2.0%

2.0%

-

Intl


1,175


1,111

5.8%

5.3%

0.5%




2,304


2,235

3.1%

4.1%

-1.0%

WW


2,469


2,385

3.5%

3.3%

0.2%




4,890


4,770

2.5%

3.0%

-0.5%

SPECIALTY SURGERY/OTHER (5)

















US


424


426

-0.5%

-0.5%

-




841


830

1.3%

1.3%

-

Intl


481


464

3.7%

4.7%

-1.0%




938


899

4.3%

6.8%

-2.5%

WW


905


890

1.7%

2.2%

-0.5%




1,779


1,729

2.9%

4.2%

-1.3%

SURGICAL CARE

















US


551


577

-4.5%

-4.5%

-




1,090


1,108

-1.6%

-1.6%

-

Intl


1,024


1,011

1.3%

1.9%

-0.6%




1,993


1,988

0.3%

2.1%

-1.8%

WW


1,575


1,588

-0.8%

-0.4%

-0.4%




3,083


3,096

-0.4%

0.8%

-1.2%

VISION CARE

















US


262


262

0.0%

0.0%

-




548


543

0.9%

0.9%

-

Intl


445


468

-4.9%

-4.0%

-0.9%




920


927

-0.8%

2.9%

-3.7%

WW


707


730

-3.2%

-2.7%

-0.5%




1,468


1,470

-0.1%

2.2%

-2.3%


















TOTAL MEDICAL DEVICES AND DIAGNOSTICS

















US


3,199


3,243

-1.4%

-1.4%

-




6,354


6,449

-1.5%

-1.5%

-

Intl


4,043


3,951

2.3%

2.6%

-0.3%




7,948


7,807

1.8%

3.6%

-1.8%

WW


$ 7,242


7,194

0.7%

0.9%

-0.2%




$ 14,302


14,256

0.3%

1.3%

-1.0%


















* Percentage greater than 100%

















(1) Operational growth excludes the effect of translational currency














(2) Unaudited

















(3) Prior year amounts have been reclassified to conform to current year product disclosure











(4) Reported as U.S. sales

















(5) Infection Prevention now reflected in Specialty Surgery/Other, previously reported independently











SOURCE Johnson & Johnson

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA, Inc., Medicine, Disease, Sexual, Surgery, Insurance, medical technologists, Cancer, Technology, Surgery, Medication, Seniors Health, Seniors, Insurance Companies, Science, Medical Technology, Medical, Business, Science, Adults, Other,

HOT THREADS on DMN Forums
Content-type: text/html

@ Copyright, 2014 Digital Media Online, All Rights Reserved